ðŠ ã³ããçŠãããæ€èšºã®æ Œå·®ã«äžããåœ±é¿ 2015幎ãã2023幎ã®èª¿æ»ç ç©¶
ããæ€èšºã¯ããããæ©æã«çºèŠããé©åãªæ²»çãžãšã€ãªããããã®éåžžã«éèŠãªææ®µã§ããæ©æçºèŠã¯æ²»çã®æåçãé«ããæ£è ããã®ç掻ã®è³ªãåäžãããäžã§æ¬ ãããŸããããããã2020幎åé ããäžççã«æ¡å€§ããæ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒã®ãã³ãããã¯ã¯ãå»çã·ã¹ãã å šäœã«å€§ããªåœ±é¿ãäžããããæ€èšºã®å蚺çäœäžãäžæãæžå¿µãããŠããŸãããæ¬ç ç©¶ã¯ããã³ãããã¯ãããæ€èšºã®å蚺çãç¹ã«æ¢åã®å¥åº·æ Œå·®ã«ã©ã®ãããªåœ±é¿ãäžããã®ããããã³ãããã¯ååŸã§æ¯èŒæ€èšŒãããã®ã§ãã
ð¬ç ç©¶ã®èæ¯ãšç®ç
ç ç©¶ã®èæ¯
ç±³åœã§ã¯1990幎代ãã2020幎ã«ãããŠãããæ€èšºã®å蚺çãçå®ã«äžæããŠããŸãããããã¯ãå ¬è¡è¡çãã£ã³ããŒã³ãå»çæè¡ã®é²æ©ãå»çã¢ã¯ã»ã¹ã®æ¹åãªã©ãè€åçã«äœçšããçµæãšèããããŸãããããããã®äžæ¹ã§ãå¹Žéœ¢ãæ§å¥ãäººçš®ã»æ°æã瀟äŒçµæžçå°äœãšãã£ãèŠå ã«ãã£ãŠãããæ€èšºã®å蚺çã«ã¯äŸç¶ãšããŠå€§ããªæ Œå·®ãååšããŠããŸãããäŸãã°ãç¹å®ã®æ°æã°ã«ãŒããäœæåŸå±€ã§ã¯ãæ€èšºãåããæ©äŒãå°ãªãåŸåãèŠãããŸããã
ãã®ãããªç¶æ³äžã§çºçããCOVID-19ãã³ãããã¯ã¯ãå»çæ©é¢ã®æ©èœåæ¢ãå蚺æ§ããå»çåŸäºè ã®äžè¶³ãææãªã¹ã¯ãžã®æžå¿µãªã©ãæ§ã ãªçç±ããããæ€èšºã®äžæãå»¶æãåŒãèµ·ãããŸãããããã«ããããããŸã§ååšããŠããå¥åº·æ Œå·®ãããã«æªåããã®ã§ã¯ãªãããšããåŒ·ãæžå¿µãæãããŠããŸãããç¹ã«ãå»çã¢ã¯ã»ã¹ãå ã éãããŠããè匱ãªéå£ã«ãããŠããã®åœ±é¿ãé¡èã«åºãå¯èœæ§ãææãããŠããŸããã
ç ç©¶ã®ç®ç
æ¬ç ç©¶ã®äž»ãªç®çã¯ãCOVID-19ãã³ãããã¯ãããæ€èšºã®å蚺çãšå¥åº·æ Œå·®ã«äžãã圱é¿ãå ·äœçã«è©äŸ¡ããããšã§ãããå ·äœçã«ã¯ããã³ãããã¯åïŒ2015-16幎ïŒãšãã³ãããã¯åŸæïŒ2021-23幎ïŒã®2ã€ã®æç¹ã«ããããå¹Žéœ¢ãæ§å¥ãäººçš®ã»æ°æãæè²ã¬ãã«ãå©å§»ç¶æ³ãåå ¥ãšãã£ã人å£çµ±èšåŠçèŠå å¥ã®ããæ€èšºçãæ¯èŒããå¥åº·æ Œå·®ãã©ã®ããã«å€åããããæããã«ããããšãç®æããŸãããããã«ããããã³ãããã¯ãæ¢åã®æ Œå·®ãæªåãããã®ãããããã¯æå€ãªåœ±é¿ããã£ãã®ããæ€èšŒããéèŠãªæããããåŸãããšããŸããã
ðç ç©¶ã®æ¹æ³
調æ»å¯Ÿè±¡è
ãã®ç ç©¶ã§ã¯ãNational Social Life, Health, and Aging Project (NSHAP) ãšããå€§èŠæš¡ãªçžŠæçã³ããŒã調æ»ã®ããŒã¿ãçšããããŸããã察象ãšãªã£ãã®ã¯ã2015-16幎ã®èª¿æ»ãš2021-23幎ã®èª¿æ»ã®äž¡æ¹ã«åçãããããæ€èšºã®å¯Ÿè±¡å¹Žéœ¢ã«è©²åœããæäºº2,585人ã§ãã瞊æçã³ããŒãç ç©¶ãšã¯ãåãå人ãé·æéã«ããã£ãŠè¿œè·¡èª¿æ»ããããšã§ãæéã®çµéã«äŒŽãå€åãèŠå ãšçµæã®é¢ä¿ã詳现ã«åæã§ããç ç©¶ãã¶ã€ã³ã§ãã
調æ»å 容
åå è ã¯ãéå»1幎éã«ä»¥äžã®ç¹å®ã®ããæ€èšºãåãããã©ãããèªå·±ç³åããŸããã
- å€§è žããæ€èšº: äž»ã«å€§è žå èŠé¡æ€æ»ïŒcolonoscopyïŒ
- ä¹³ããæ€èšº: äž»ã«ãã³ã¢ã°ã©ãã£ãŒïŒmammogramïŒ
ïŒä¹³æ¿ã®Xç·æ®åœ±ã§ãä¹³ããã®æ©æçºèŠã«çšããããç»åèšºææ³ã§ããïŒ - åç«è
ºããæ€èšº: äž»ã«PSAæ€æ»ïŒprostate-specific antigen testingïŒ
ïŒè¡æ¶²äžã®åç«è ºç¹ç°æåïŒPSAïŒã®å€ã枬å®ããæ€æ»ã§ãåç«è ºããã®ã¹ã¯ãªãŒãã³ã°ã«å©çšãããŸããïŒ
èªå·±ç³åããŒã¿ã¯ãå®éã®æ€èšºèšé²ãšæ¯èŒããŠèšæ¶ã®äžæ£ç¢ºãã瀟äŒçæãŸããã®ãã€ã¢ã¹ãå«ãŸããå¯èœæ§ã¯ãããŸãããå€§èŠæš¡ãªç«åŠç ç©¶ã§ã¯åºãçšããããææ³ã§ãã
åææ¹æ³
åéãããããŒã¿ã¯ãåå€éããã³å€å€éããžã¹ãã£ãã¯ååž°åæãçšããŠçµ±èšçã«åæãããŸãããããžã¹ãã£ãã¯ååž°åæãšã¯ãããäºè±¡ïŒãã®å Žåã¯ããæ€èšºã®å蚺ïŒãèµ·ãã確çããè€æ°ã®èŠå ïŒå¹Žéœ¢ãæ§å¥ãäººçš®ã»æ°æãæè²ã¬ãã«ãå©å§»ç¶æ³ãåå ¥ãªã©ïŒããäºæž¬ããçµ±èšææ³ã§ãããã®åæã«ãããå人å£çµ±èšåŠçèŠå ãããæ€èšºå蚺çã«äžãã圱é¿ã®å€§ããããèŠå éã®çžäºäœçšãè©äŸ¡ããããšãå¯èœãšãªããŸãã
ð¡äž»ãªç ç©¶çµæ
æ¬ç ç©¶ã§åŸãããäž»èŠãªçµæã¯ä»¥äžã®éãã§ãã
| é ç® | 2015-16幎ïŒãã³ãããã¯åïŒ | 2021-23幎ïŒãã³ãããã¯åŸæïŒ | äž»ãªåŸåãšçµ±èšçæææ§ |
|---|---|---|---|
| å šäœçãªæ€èšºç | å€åãªã | å€åãªã | å€§è žå èŠé¡æ€æ»ããã³ã¢ã°ã©ãã£ãŒãPSAæ€æ»ã®ããããããã³ãããã¯ååŸã§å šäœçãªå蚺çã«ææãªå€åã¯èŠãããŸããã§ããã |
| 幎霢å¥ïŒè¥å¹Žå±€ vs é«éœ¢å±€ïŒ | è¥å¹Žå±€ïŒ60æ³æªæºïŒã®ãã³ã¢ã°ã©ãã£ãŒç: 52.8% vs 62.9% (p=0.04) è¥å¹Žå±€ã®PSAæ€æ»ç: 37.0% vs 53.5% (p<0.001) |
è¥å¹Žå±€ã®PSAæ€æ»ç: 34.3% vs 45.3% (p=0.04) | è¥å¹Žå±€ïŒ60æ³æªæºïŒã¯ããã³ãããã¯åãåŸæããé«éœ¢å±€ã«æ¯ã¹ãŠãã³ã¢ã°ã©ãã£ãŒãšPSAæ€æ»ã®å蚺çãäœãåŸåãç¶ç¶ããŠããŸããã |
| äººçš®ã»æ°æå¥ | ãã¹ãããã¯ç³»ã®å€§è
žå
èŠé¡æ€æ»ç: 12.1% (p=0.006) é»äººå¥³æ§ã®ãã³ã¢ã°ã©ãã£ãŒç: 65.3% (p=0.04) |
ãã¹ãããã¯ç³»ã®å€§è žå èŠé¡æ€æ»ç: 7.6% (p=0.002) | ãã¹ãããã¯ç³»ã¯ããã³ãããã¯ååŸãéããŠå€§è žå èŠé¡æ€æ»ã®å蚺çãæãäœããŸãŸã§ãããé»äººå¥³æ§ã¯ãã³ãããã¯åã«ã¯ãã³ã¢ã°ã©ãã£ãŒå蚺çãæãé«ãã£ãã§ããããã³ãããã¯åŸæã«ãããææãªå·®ã¯ç€ºãããŸããã§ããã |
| å©å§»ç¶æ³å¥ïŒç·æ§ïŒ | æªå©ç·æ§ã®PSAæ€æ»çãæ¢å©ç·æ§ããäœã (p=0.02) | æªå©ç·æ§ã®PSAæ€æ»çãæ¢å©ç·æ§ããäœã (p=0.005) | æªå©ç·æ§ã¯ããã³ãããã¯ååŸãéããŠæ¢å©ç·æ§ã«æ¯ã¹ãŠPSAæ€æ»ã®å蚺çãäœãåŸåãç¶ç¶ããŠããŸããã |
| åå ¥å¥ | äœæåŸè å±€ã®å šãŠã®æ€èšºçãäœã (p<0.05) | ç¹èšãã¹ãææå·®ãªã | ãã³ãããã¯åã«ã¯ãäœæåŸè å±€ã§å šãŠã®ããæ€èšºã®å蚺çãäœãããšã瀺ãããŸããããã³ãããã¯åŸæã«ãããåå ¥ãšæ€èšºçã®ææãªå·®ã¯ãä»åã®åæã§ã¯æç¢ºã«ç€ºãããŸããã§ããã |
éèŠãªç¹ãšããŠãåæã®çµæãæéã®çµéãšãšãã«æ€èšºçã«ããã人å£çµ±èšåŠçå·®ç°ãææã«å€åãããšããå åã¯ç€ºãããŸããã§ãããã€ãŸãããã³ãããã¯ã«ãã£ãŠç¹å®ã®ãµãã°ã«ãŒããäžåè¡¡ã«åœ±é¿ãåãããšããæç¢ºãªèšŒæ ã¯èŠã€ãããªãã£ããšããããšã§ãã
ð§ç ç©¶çµæããèŠããŠããããšïŒèå¯ïŒ
æ¬ç ç©¶ã®æãæ³šç®ãã¹ãçµè«ã¯ãCOVID-19ãã³ãããã¯ã«ãã£ãŠããæ€èšºã®å šäœçãªå蚺çãäœäžããªãã£ãããšã§ããããã¯ããã³ãããã¯åæã®æžå¿µãšã¯ç°ãªãçµæã§ãããç±³åœã®å»çã·ã¹ãã ããã³ãããã¯ã®æ··ä¹±æã«ãããŠããããæ€èšºã®æäŸãç¶æããããšåªããããšããããã¯äººã ãæ€èšºã®éèŠæ§ãèªèããå蚺ãç¶ç¶ããããšã瀺åããŠããå¯èœæ§ããããŸãããããããã®ãå šäœçãªå€åãªãããšããçµæã®è£ã«ã¯ãããè€éãªå®æ ãé ãããŠãããããããŸããã
ãŸããæ¢åã®å¥åº·æ Œå·®ããã³ãããã¯ã«ãã£ãŠæªåããªãã£ããšããç¹ã¯ãããæå³ã§å®å µãã¹ãçµæãšèšããŸããããããããã¯ãæ Œå·®ãè§£æ¶ããããããšãæå³ãããã®ã§ã¯ãªãããæ Œå·®ããã®ãŸãŸç¶æãããããšããããšã瀺ããŠããŸããè¥å¹Žå±€ããã¹ãããã¯ç³»ã®äººã ãäœæåŸè å±€ããããŠæªå©ç·æ§ãšãã£ãç¹å®ã®äººå£çµ±èšåŠçã°ã«ãŒãã§ã¯ããã³ãããã¯åããããæ€èšºã®å蚺çãäœãåŸåã«ããããã®åŸåããã³ãããã¯åŸãç¶ç¶ããŠããããšãæããã«ãªããŸãããããã¯ããããã®ã°ã«ãŒããå»çã¢ã¯ã»ã¹ãå¥åº·ãªãã©ã·ãŒãçµæžçéå£ããããã¯æåçãªèŠå ãªã©ãæ§ã ãªèª²é¡ã«çŽé¢ãç¶ããŠããããšã瀺åããŠããŸãã
äŸãã°ããã¹ãããã¯ç³»ã®äººã ã«ãããå€§è žããæ€èšºã®äœãå蚺çã¯ãèšèªã®å£ãæåçãªçè§£ã®æ¬ åŠãå»çä¿éºãžã®ã¢ã¯ã»ã¹äžè¶³ããããã¯æ€èšºã«å¯Ÿããæèã®éããªã©ãè€åçã«åœ±é¿ããŠããå¯èœæ§ããããŸãããŸããè¥å¹Žå±€ã®æ€èšºçã®äœãã¯ãããã®ãªã¹ã¯ãäœããšããèªèããå€å¿ãªç掻ã®äžã§æ€èšºãåªå ãã«ãããšãã£ãèŠå ãèããããŸããæªå©ç·æ§ã®PSAæ€æ»çãäœãã®ã¯ãããŒãããŒããã®å¥åº·ãžã®åãããããªãããšããå¥åº·ã«å¯Ÿããæèã®éãã圱é¿ããŠããã®ãããããŸããã
äžæ¹ã§ãé»äººå¥³æ§ã®ãã³ã¢ã°ã©ãã£ãŒå蚺çããã³ãããã¯åã«ã¯æãé«ãã£ããšããçµæã¯è峿·±ãç¹ã§ããããã¯ãç¹å®ã®ã³ãã¥ããã£ã«ãããå¥åº·åçºæŽ»åã®æåããå»çæ©é¢ãšã®é£æºã广çã«æ©èœããŠããå¯èœæ§ã瀺åããŠããŸãããããããã³ãããã¯åŸæã«ã¯ãã®ææãªå·®ã瀺ãããªãã£ãããšãããäœããã®å€åããã£ãå¯èœæ§ãèããããŸãã
ãã®ç ç©¶çµæã¯ããã³ãããã¯ãå»çã·ã¹ãã ã«äžãã圱é¿ããå¿ ãããäžæ¹åçã§ã¯ãªãããšã瀺ããŠããŸããç·æ¥äºæ äžã«ãããŠããããæ€èšºã®ãããªäºé²å»çã®éèŠæ§ãåèªèãããå»çæäŸè åŽããã®ç¶æã«åªããå¯èœæ§ããããŸãããããããã³ãããã¯ãæ¢åã®æ Œå·®ãæªåãããªãã£ããšããŠãããã®æ Œå·®èªäœãäŸç¶ãšããŠååšããç¹å®ã®ã°ã«ãŒããããã®æ©æçºèŠã®æ©æµãåãã«ããç¶æ³ã«ããããšã¯ãå ¬è¡è¡çäžã®å€§ããªèª²é¡ã§ããç¶ããŠããŸãããããã£ãŠããããã®æ Œå·®ãè§£æ¶ããããã®ãããã¿ãŒã²ãããçµã£ãä»å ¥çãåŒãç¶ãå¿ èŠã§ãããšèšããã§ãããã
ðå®ç掻ãžã®ã¢ããã€ã¹
æ¬ç ç©¶ã®çµæãèžãŸããç§ãã¡äžäººã²ãšããå¥åº·ãå®ãããŸã瀟äŒå šäœãšããŠå¥åº·æ Œå·®ãæ¯æ£ããŠããããã«ã以äžã®ç¹ãå®ç掻ã«åãå ¥ããããšãéèŠã§ãã
- 宿çãªããæ€èšºã®ç¶ç¶: ãã³ãããã¯ã®æç¡ã«ããããããããæ€èšºã¯ããã®æ©æçºèŠã«äžå¯æ¬ ã§ããèªæ²»äœãè·å Žã®æ€èšºããããã€ãå»ãšã®çžè«ãéããŠãæšå¥šãããæ€èšºã宿çã«å蚺ããŸãããã
- èªèº«ã®å¥åº·ç¶æ ãšãªã¹ã¯ã®ææ¡: å®¶æã«ããã®æ¢åŸæŽãããå Žåããç¹å®ã®çæŽ»ç¿æ £ïŒå«ç ãé床ã®é£²é ãªã©ïŒãããå Žåã¯ãéåžžããããªã¹ã¯ãé«ãå¯èœæ§ããããŸããå»åž«ãšçžè«ããåå¥ã®æ€èšºèšç»ãç«ãŠãããšã倧åã§ãã
- å»çæ©é¢ãšã®è¯å¥œãªé¢ä¿æ§ç¯: ãããã€ãå»ãæã€ããšã§ãå¥åº·ã«é¢ããçžè«ããããããªããé©åãªã¿ã€ãã³ã°ã§æ€èšºãå°éå»ãžã®ç޹ä»ãåããããšãã§ããŸãã
- å¥åº·æ å ±ã®ç©æ¥µçãªåé: ä¿¡é Œã§ããæ å ±æºïŒåçåŽåçãåœç«ããç ç©¶ã»ã³ã¿ãŒãåŠäŒãªã©ïŒããããããæ€èšºã«é¢ããææ°æ å ±ãåŸãŠãèªèº«ã®å¥åº·ãªãã©ã·ãŒãé«ããŸãããã
- åšå²ãžã®å£°ãããšãµããŒã: ç¹ã«ãæ€èšºçãäœãåŸåã«ããè¥å¹Žå±€ãç·æ§ãç¹å®ã®æ°æã°ã«ãŒãã®å人ãå®¶æã«å¯ŸããŠãããæ€èšºã®éèŠæ§ãäŒããå蚺ãä¿ã声ãããæå¹ã§ããå¿ èŠã§ããã°ãå»çæ©é¢ãžã®äºçŽãæ å ±åéãæäŒããªã©ã®ãµããŒããæ€èšããŸãããã
- 瀟äŒçãªæ¯æŽå¶åºŠã®æŽ»çš: çµæžçãªçç±ã§æ€èšºãé£ããå Žåã¯ãèªæ²»äœãå»çæ©é¢ãæäŸããæ€èšºè²»çšå©æå¶åºŠãç¡ææ€èšºããã°ã©ã ããªãã確èªããç©æ¥µçã«æŽ»çšããŸãããã
ð§ç ç©¶ã®éçãšä»åŸã®èª²é¡
æ¬ç ç©¶ã¯éèŠãªç¥èŠãæäŸããŸããããããã€ãã®éçãååšããŸãã
- èªå·±ç³åããŒã¿: æ€èšºã®åèšºç¶æ³ã¯èªå·±ç³åã«åºã¥ããŠãããããèšæ¶ã®äžæ£ç¢ºããã瀟äŒçã«æãŸããåçãããããšãããã€ã¢ã¹ãå«ãŸããå¯èœæ§ããããŸããããã«ãããå®éã®å蚺çãé倧ãŸãã¯éå°ã«è©äŸ¡ãããŠããå¯èœæ§ãåŠå®ã§ããŸããã
- ç±³åœããŒã¿ã§ããããš: ãã®ç ç©¶ã¯ç±³åœã®åå è ã察象ãšããŠããããã®çµæãæ¥æ¬ã®å»çã·ã¹ãã ãç€ŸäŒæåã«ãã®ãŸãŸåœãŠã¯ãŸããšã¯éããŸãããååœã®å»çå¶åºŠãå¥åº·æèã®éããèæ ®ããå¿ èŠããããŸãã
- ãã³ãããã¯åŸæã®ã¿ã®æ¯èŒ: ãã³ãããã¯ã®ãåŸæãã®ããŒã¿ãšæ¯èŒããŠããŸããããã³ãããã¯ãæãæ·±å»ã ã£ãææïŒäŸãã°2020幎ïŒã®çæçãªæ€èšºäžæã®åœ±é¿ã¯ããã®ç ç©¶ã§ã¯çŽæ¥çã«æããããŠããŸãããäžæçãªå€§å¹ ãªèœã¡èŸŒã¿ããã£ãåŸã«å埩ããå¯èœæ§ãèããããŸãã
- ç¹å®ã®æ€èšºã«éå®: å€§è žãããä¹³ãããåç«è ºããã®3çš®é¡ã®ããæ€èšºã«çŠç¹ãåœãŠãŠããŸãããä»ã®ããçš®ïŒèºãããåå®®é žãããªã©ïŒã®æ€èšºã«ã€ããŠã¯è©äŸ¡ãããŠããŸããã
- æ Œå·®ã®èŠå ã®æ·±æãäžè¶³: 人å£çµ±èšåŠçèŠå ã«ããæ Œå·®ã¯ç€ºãããŸãããããã®èæ¯ã«ããå ·äœçãªéå£ïŒå»çã¢ã¯ã»ã¹ã®åé¡ãä¿éºã®æç¡ãæåçãªä¿¡å¿µãå¥åº·ãªãã©ã·ãŒãªã©ïŒã«ã€ããŠã¯ããã詳现ãªè³ªçã»éçç ç©¶ãå¿ èŠã§ãã
ä»åŸã®ç ç©¶ã§ã¯ããããã®éçãå æãããã詳现ãªããŒã¿ïŒå»çèšé²ã«åºã¥ãæ€èšºçããã³ãããã¯ã®å段éã§ã®å€åãæ Œå·®ã®èæ¯ã«ããå ·äœçãªéå£ïŒãçšããŠãããæ€èšºã®æ Œå·®è§£æ¶ã«åãã广çãªä»å ¥çãéçºããŠããããšã課é¡ãšãªããŸãã
æ¬ç ç©¶ã¯ãCOVID-19ãã³ãããã¯ãããæ€èšºã®å šäœçãªå蚺çã倧ããäœäžãããããšã¯ãªãã£ããã®ã®ããã³ãããã¯åããååšããŠããå¥åº·æ Œå·®ãè§£æ¶ãããããšãªãç¶ç¶ããŠããããšãæããã«ããŸãããç¹ã«ãè¥å¹Žå±€ããã¹ãããã¯ç³»ã®äººã ãäœæåŸè å±€ãæªå©ç·æ§ãšãã£ãç¹å®ã®äººå£çµ±èšåŠçã°ã«ãŒãã§ã¯ãããæ€èšºã®å蚺çãäœãåŸåãç¶ããŠããããããã®ã°ã«ãŒãã«å¯Ÿããã¿ãŒã²ãããçµã£ãåçºæŽ»åãæ¯æŽçãåŒãç¶ãäžå¯æ¬ ã§ããããšã匷ã瀺åããŠããŸããããã®æ©æçºèŠãšæ²»çã®æ©æµã誰ãã享åã§ãã瀟äŒãç®æããæç¶çãªåªåãæ±ããããŸãã
é¢é£ãªã³ã¯é
- åçåŽåç
- åœç«ããç ç©¶ã»ã³ã¿ãŒ
- å ¬çè²¡å£æ³äºº æ¥æ¬å¯ŸããåäŒ
- National Cancer Institute (NCI) – ç±³åœåœç«ããç ç©¶æ
- äžçä¿å¥æ©é¢ (WHO) – ãã
æžèªæ å ±
| DOI | 10.1007/s11606-026-10634-w |
|---|---|
| PMID | 42463628 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/42463628/ |
| çºè¡å¹Ž | 2026 |
| èè å | Vuppaladhadiam Lahari, Wroblewski Kristen, Schumm Phil, Tiro Jasmin, Hawkley Louise, McClintock Martha, Huang Elbert S |
| èè æå± | Pritzker School of Medicine, University of Chicago, Chicago, IL, USA. lahariv@uchicagomedicine.org.; Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.; Center for Translational Data Science, University of Chicago, Chicago, IL, USA.; The Bridge at NORC at the University of Chicago, Chicago, IL, USA.; Department of Psychology and Institute for Mind and Biology, The University of Chicago, Chicago, IL, USA. |
| éèªå | J Gen Intern Med |